Zhejiang Starry Pharm Co Ltd - Asset Resilience Ratio

Latest as of December 2023: 0.00%

Zhejiang Starry Pharm Co Ltd (603520) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Zhejiang Starry Pharm Co Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥23.15K
≈ $3.39K USD Cash + Short-term Investments

Total Assets

CN¥5.52 Billion
≈ $807.58 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how Zhejiang Starry Pharm Co Ltd's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Zhejiang Starry Pharm Co Ltd to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Zhejiang Starry Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603520 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥23.15K 0.0%
Total Liquid Assets CN¥23.15K 0.00%

Asset Resilience Insights

  • Limited Liquidity: Zhejiang Starry Pharm Co Ltd maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Zhejiang Starry Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Zhejiang Starry Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 0.76%
Eris Lifesciences Limited
NSE:ERIS
Drug Manufacturers - Specialty & Generic 0.58%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.01%
Lotus Pharmaceutical Co Ltd
TW:1795
Drug Manufacturers - Specialty & Generic 0.49%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 11.69%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 18.70%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Sun Pharma Advanced Research Company Limited
NSE:SPARC
Drug Manufacturers - Specialty & Generic 0.64%

Annual Asset Resilience Ratio for Zhejiang Starry Pharm Co Ltd (2016–2023)

The table below shows the annual Asset Resilience Ratio data for Zhejiang Starry Pharm Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.00% CN¥23.15K
≈ $3.39K
CN¥5.52 Billion
≈ $807.23 Million
-0.02pp
2022-12-31 0.02% CN¥876.69K
≈ $128.29K
CN¥5.30 Billion
≈ $775.88 Million
-1.42pp
2021-12-31 1.43% CN¥70.16 Million
≈ $10.27 Million
CN¥4.90 Billion
≈ $716.35 Million
-1.53pp
2020-12-31 2.97% CN¥130.76 Million
≈ $19.13 Million
CN¥4.41 Billion
≈ $644.79 Million
+2.47pp
2017-12-31 0.50% CN¥10.00 Million
≈ $1.46 Million
CN¥2.01 Billion
≈ $294.62 Million
-3.20pp
2016-12-31 3.70% CN¥70.00 Million
≈ $10.24 Million
CN¥1.89 Billion
≈ $277.08 Million
--
pp = percentage points

About Zhejiang Starry Pharm Co Ltd

SHG:603520 China Drug Manufacturers - Specialty & Generic
Market Cap
$610.74 Million
CN¥4.17 Billion CNY
Market Cap Rank
#11384 Global
#3248 in China
Share Price
CN¥9.52
Change (1 day)
+1.28%
52-Week Range
CN¥9.14 - CN¥13.75
All Time High
CN¥651.92
About

Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more